India Must Institutionalize Risk-Based Inspections, Harness AI For Pharmacovigilance, Says Panel

 
• By Anju Ghangurde
  
recommendation
Parliamentary panel makes recommendations on key aspects of India’s drug regulatory system (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Regulatory Pathways

More from Pink Sheet